Phenominer Database Results (14 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Experiment Notes Record ID Study ID
DA/Ztm post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 median 14.0 d in vivo visual assessment 0.0 0 69637 1161
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 9 100.0 % in vivo visual assessment 0.0 0 69720 1162
DA/Ztm serum orosomucoid 1 level squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 9 790.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69767 1162
DA/Ztm post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 9 14.0 d 0.7 2.1 in vivo visual assessment 0.0 0 69788 1162
DA/Ztm maximum body weight loss to initial body weight ratio squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 9 12.8 % 0.9 2.7 body weighing method 0.0 0 69807 1162
DA/Ztm subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 38.0 % in vivo visual assessment 0.0 0 69630 1161
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 100.0 % in vivo visual assessment 0.0 0 69703 1162
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 100.0 % in vivo visual assessment 0.0 0 69625 1161
DA/Ztm post-insult time to onset of experimental arthritis squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 median 14.0 d in vivo visual assessment 0.0 0 69636 1161
DA/Ztm percentage of study population developing experimental arthritis during a period of time squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait female 0 days 8 100.0 % in vivo visual assessment 0.0 0 69624 1161
DA/Ztm subjects with ankylosis to total subjects with arthritis ratio squalene (860 mg/ml) Holm BC, et al., Hum Mol Genet 2001 Mar 15;10(6):565-72. joint integrity trait male 0 days 6 50.0 % in vivo visual assessment 0.0 0 69631 1161
DA/Ztm serum orosomucoid 1 level squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. orosomucoid 1 amount both 120 days-180 days 15 1060.0 mg/l radial immunodiffusion assay 0.0 0 radial immunodiffusion assay blood alpha-1-acid glycoprotein amount 69750 1162
DA/Ztm maximum body weight loss to initial body weight ratio squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. body mass both 120 days-200 days 15 12.8 % 0.6 2.32 body weighing method 0.0 0 69794 1162
DA/Ztm post-insult time to onset of experimental arthritis squalene (200 ul) Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9. joint integrity trait both 120 days-200 days 15 13.0 d 0.4 1.55 in vivo visual assessment 0.0 0 69773 1162